{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7127","pValueComment":"Stratified by region, prior biologic use, RF status and treatment.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1018","pValueComment":"Stratified by region, prior biologic use, RF status and treatment.","statisticalMethod":"ANOVA","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.38","upperLimit":"-1.87","value":"-2.13"},{"groupId":"OG001","lowerLimit":"-2.45","upperLimit":"-1.92","value":"-2.19"},{"groupId":"OG002","lowerLimit":"-2.71","upperLimit":"-2.12","value":"-2.42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"118"},{"groupId":"OG002","value":"93"}],"units":"Participants"}],"description":"DAS28 was calculated according to the following formula: DAS28 equals (=) \\[0.56 multiplied by (\\*) the square root (√) of TJC\\] plus (+) \\[0.28 \\* √ of SJC\\] + (0.70 \\* the natural logarithm (ln) ESR in millimeters per hour (mm/h)\\] + \\[0.014 \\* participant's global assessment of disease activity (GH)\\]. DAS28-ESR ≥ 5.1 = high disease activity, DAS28-ESR less than or equal to (≤) 3.2 = low disease activity, DAS28-ESR less than (\\<) 2.6 = remission.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received rituximab, 0.5 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG000","title":"Rituximab Low Dose + Methotrexate"},{"description":"Participants received rituximab, 0.5 g, IV, on Days 1 and 15 and 1.0 g, IV, on Days 168 and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG001","title":"Rituximab Escalated Dose + Methotrexate"},{"description":"Participants received rituximab, 1.0 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG002","title":"Rituximab High Dose + Methotrexate"}],"paramType":"MEAN","populationDescription":"ITT-M2 population. Two participants from the Low Dose group and 1 participant from the Escalated Dose group were not evaluated for this outcome measure.","reportingStatus":"POSTED","timeFrame":"BL, Week 48","title":"Disease Activity Score Based on 28-Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR): Adjusted Mean Change From BL at Week 48","type":"SECONDARY","unitOfMeasure":"score on a scale"}